Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Enlivex Therapeutics Ltd. Major Shareholding Notification 2019

Sep 10, 2019

6778_rns_2019-09-10_94b2f8be-0760-46ef-921d-aacfe45f87da.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Act of 1934 (Amendment No. 1)

ENLIVEX THERAPEUTICS LTD.

(Name of Issuer)

Ordinary Shares, par value NIS 0.40 per share (Title of Class of Securities)

M4130Y106

(CUSIP Number)

September 1, 2019

(Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

  • ☐ Rule 13d-1(b)
  • ☒ Rule 13d-1(c)
  • ☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1 NAME OF REPORTING PERSON
Michael Hobi
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5 SOLE VOTING POWER 498,432
6 SHARED VOTING POWER 0
7 SOLE DISPOSITIVE POWER 498,432
8 SHARED DISPOSITIVE POWER 0
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
498,432
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.93%(1)
12 TYPE OF REPORTING PERSON
IN

(1) Based on 10,113,707 ordinary shares issued and outstanding as of June 5, 2019.

2

Item 1(a) Name of Issuer:

Enlivex Therapeutics Ltd. (the "Issuer")

Item 1(b) Address of Issuer's Principal Executive Offices:

14 Einstein Street, Nes Ziona, Israel 7403618.

Item 2(a) Name of Person Filing:

Michael Hobi

Item 2(b) Address or Principal Business Office or, if none, Residence:

Färberstrasse 4 CH-8832 Wollerau Switzerland

Item 2(c) Citizenship:

Switzerland

Item 2(d) Title of Class of Securities:

Ordinary shares, NIS 0.40 per share

Item 2(e) CUSIP Number:

M4130Y106

Item 3 If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4 Ownership.

Number of
Outstanding Percentage
Ordinary of
Shares Outstanding
Beneficially Ordinary
Reporting Person Owned Shares (1)
Michael Hobi (2) 498,432 4.93%

(1) Percentage based upon 10,113,707 ordinary shares issued and outstanding as of June 5, 2019.

(2) Michael Hobi has sole voting and dispositive power over all reported shares.

Item 5 Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

Item 6 Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8 Identification and Classification of Members of the Group.

Not applicable.

Item 9 Notice of Dissolution of Group.

Not applicable.

Item 10 Certifications.

Not applicable.

SIGNATURES

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: September 9, 2019 Michael Hobi

/s/ Michael Hobi

5